TrialJournal of experimental & clinical cancer research : CR2022

Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment.

Daniela A Bota et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.